New research out of Harvard Medical School suggests that lithium deficiency may be a key driver of Alzheimer’s disease and a promising target for early diagnosis and treatment. Harvard’s Office of Technology Development has protected the innovations related to this research and is actively seeking industry partners for commercialization to advance these discoveries.

A lab at Harvard T.H. Chan School of Public Health received industry-sponsored research and aims to translate discoveries about a protein that helps regulate metabolism and inflammation into novel therapeutics for obesity, heart disease, and age-related illnesses.

Novo Nordisk and Evotec selected three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseases.

Harvard researchers have pioneered a groundbreaking method for generating large numbers of adult skeletal-muscle satellite cells, also known as muscle stem cells, in vitro.